Rakovina Therapeutics Inc. has extended the maturity date of its Convertible Debentures from November 29, 2025 to January 28, 2026. The Extension was approved by Debentureholders representing at least 66 2/3% of the outstanding principal. The Company plans to amend the terms of the Indenture with the Debenture Trustee to reflect the Extension. Certain directors own approximately $100,000 of the Convertible Debentures. The Company’s early exercise warrant incentive program expired on September 2, 2025 with no warrants exercised. Rakovina Therapeutics focuses on cancer treatments using AI-enabled drug discovery.

For more information, contact Michelle Seltenrich, Director of Corporate Development at [email protected] or 778-773-5432.

Read more at GlobeNewswire: Rakovina Therapeutics Announces Debentureholder Approval of